The Food and Drug Administration late last night amended Pfizer’s emergency use authorization for its COVID-19 vaccine to allow for an additional, booster dose for certain individuals. FDA will authorize a booster shot to be administered six months following a completed two-dose regiment for the following:

  • individuals 65 years of age and older; 
  • individuals in the 18-64 age range who are at high risk of severe COVID-19; and
  • individuals in the 18-64 age range whose frequent institutional or occupational exposure to SARS-CoV-2 puts them at high risk of serious complications of COVID-19, including severe disease.

The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices today advanced the possibility of booster shots, voting unanimously to recommend boosters for the 65-and-older age group and people in long-term care facilities. ACIP also fully recommended giving a single booster dose to people between the ages of 50 and 64 with certain high risk conditions.

The ACIP meeting was continuing at the time of AHA Today’s publication, with the committee discussing occupational exposure issues that may warrant a booster. AHA tomorrow will update members on this issue.

Related News Articles

Headline
The AHA provided recommendations to the Food and Drug Administration Dec. 1 in response to a request for information on the measurement and evaluation of…
Headline
The Food and Drug Administration has identified a Class I recall of Baxter Life2000 Ventilation Systems due to a cybersecurity issue discovered through…
Headline
The Food and Drug Administration yesterday published an announcement from Otsuka ICU Medical saying that the company issued a voluntary recall for a mislabeled…
Headline
The Centers for Disease Control and Prevention will update its immunization schedules for the COVID-19 and chickenpox vaccines to adopt recent recommendations…
Headline
The Food and Drug Administration today issued a request for public comment on a series of questions regarding current approaches to evaluating artificial…
Headline
The Food and Drug Administration yesterday announced that Olympus issued a global recall of its ViziShot 2 FLEX needles manufactured prior to May 12 following…